Treprostinil

Drug Levels and Effects:




Summary of Use during Lactation:


One patient taking treprostinil breastfed her infant for one year without any complications. If treprostinil is required by the mother, it is not a reason to discontinue breastfeeding. However, until more data are available, treprostinil should only be used with careful monitoring during breastfeeding.


Drug Levels:


Maternal Levels.

Relevant published information was not found as of the revision date.

Infant Levels.

Relevant published information was not found as of the revision date.


Effects in Breastfed Infants:


A woman developed pulmonary artery hypertension and was treated with intravenous treprostinil beginning at 32 weeks of gestation and titrated up to 26 ng/kg/min. The dose was nearly doubled postpartum because of worsening symptoms. She breastfed (extent not stated) her infant for one year with no apparent drug-related problems, although there was concern for obesity at 6 months of age. The infant was healthy and developing normally at 2 years of age.[1]


Possible Effects on Lactation:


Relevant published information was not found as of the revision date.


References:


1. Franco V, Mueller J, Daniels CJ. Is the use of remodulin safe for pregnant and breastfeeding patients with pulmonary arterial hypertension (PAH)? A case report. J Heart Lung Transplant. 2012;31 (Suppl. S):S71. Abstract.



Substance Identification:




Substance Name:

Treprostinil

CAS Registry Number:

81846-19-7

Drug Class:


  • Antihypertensive Agents

  • Prostaglandins


  • Administrative Information:




    LactMed Record Number:


    998


    Last Revision Date:


    Disclaimer:Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.